QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-celcuity-maintains-70-price-target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

 celcuity-to-present-phase-3-viktoria-1-breast-cancer-data-in-late-breaking-oral-session-at-esmo-2025

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

 guggenheim-initiates-coverage-on-celcuity-with-buy-rating-announces-price-target-of-110

Guggenheim analyst Brad Canino initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of ...

 celcuitys-nda-for-gedatolisib-in-hrher2--breast-cancer-accepted-into-fdas-real-time-oncology-review-program

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

 hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-66

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

 needham-maintains-buy-on-celcuity-lowers-price-target-to-70

Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $74 to $70.

 celcuity-q2-adj-eps-093-misses-088-estimate

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.88) by...

 leerink-partners-maintains-outperform-on-celcuity-raises-price-target-to-60

Leerink Partners analyst Andrew Berens maintains Celcuity (NASDAQ:CELC) with a Outperform and raises the price target from $...

 hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-50

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

 celcuity-stock-skyrockets-on-breakthrough-trial-data-for-heavily-pretreated-breast-cancer

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected in...

 needham-reiterates-buy-on-celcuity-maintains-29-price-target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $29 price target.

Core News & Articles
Market-Moving News for July 28th
07/28/2025 11:36:15

CELC: 133% | Celcuity Released Topline Results From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Trial Of Gedatolisib Plus Ful...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION